Nightstar治療 NITE 深 滬
等待開盤 08-14 09:30:00 美东时间
32.9202
+0.358
+1.10%
華盛通- 最 高32.9202
- 今 開32.90
- 成交量 302股
- 最 低 32.86
- 昨 收 32.5618
- 總市值 2711.64万
- 52周最高 32.9202
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 22.38
- 委 比 0.00%
- 總股本 82.37万
- 歷史最高 32.9202
- 量 比 0
- 振 幅 0.18%
- 歷史最低 10.99
- 每 手 1
- 風險率 2.64%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多ClearPoint Neuro Achieves Key Milestones With First U.S. Commercial Gene Therapy Infusions Using SmartFlow Device For AADC Deficiency
ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced multiple key milestones demonstrating the
08-05 04:37
Clorox Reports Q4 and FY25 Results, Provides FY26 Outlook
Delivers strong margin expansion and adjusted EPS growth for FY25 despite challenging environment in the second half of the fiscal year OAKLAND, Calif., July 31, 2025 /PRNewswire/ -- The Clo...
08-01 04:10
Tesla's Earnings Flop Trips Up These ETFs
Tesla's Q2 results bad for high exposure ETFs. TSLA stock recovers, others dip. Risk in funds with Tesla: TESL, XLY, NITE, FDIS, VCR. Sales lag, Musk's moonshots may not save reputation.
07-26 02:41
“快闪”赋能，新场景激活消费“新流量”
潮玩新空间 城市对话窗 “快闪”赋能，新场景激活消费“新流量” □南京日报/紫金山新闻记者 黄琳燕 7月20日，江宁景枫中心的中庭成为“MINIT...
07-21 07:17
哪些A股上市公司有家族信托持股？
（转自：券研社） 在资本市场日益成熟的今天，家族信托作为一种高效、灵活的财富管理与传承工具，正逐渐在A股市场崭露头角。 1、内地民企海外上市+海外家族信托 家族...
07-07 23:09
Fresenius Launches 'FME Reignite' With $1B Annual Capex Plan and $1.05B Cost Savings Target by 2027
Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, today unveiled its new FME Reignite strategy at its Capital Markets Day in London. FME Reignite
06-17 19:11
How Musk's Political Drama With Trump Steers These 3 Tesla ETFs
Tesla's whiplash was also reflected in its ETF entourage, including Simplify Volt TSLA Revolution ETF and Roundhill TSLA WeeklyPay ETF.
06-17 01:13
Vigil Neuroscience fails in mid-stage study for lead asset
Vigil Neuroscience (NASDAQ:VIGL) announced on Wednesday that a mid-stage trial for its lead candidate, iluzanebart, didn’t succeed in patients with a rare neurological disease called adult-onset leuko...
06-04 19:26
Vigil Neuroscience Discontinues Phase 2 Extension Study For Iluzanebart After Trial Results
Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced an update on the Phase 2
06-04 19:16
Clorox Reports Q3 Fiscal Year 2025 Results, Updates Outlook
Delivers lower-than-expected sales amid a challenging and volatile consumer and geopolitical environment while maintaining overall market shares and delivering its 10th consecutive quarter o...
05-06 04:10
